Joseph F. Johnston - Concepedia

Concepedia

Author

Joseph F. Johnston

Ionis Pharmaceuticals (United States)

Also Known As

J F Johnston, J Johnston, J. Johnston, J.F. Johnston, JOSEPH F. JOHNSTON, Johnston, J., Joseph F. Johnston, Joseph F. Johnston

15

Publications

1.8K

Citations

11

H-Index

33

Concepts

All Affiliations

Ionis Pharmaceuticals (United States)Novartis (Switzerland)

JF

About

Joseph F. Johnston is an author at Ionis Pharmaceuticals (United States) specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	1.3K
2	Natural Sciences	2	2	535
3	Health Sciences	1	1	235
4	Allergy	1	1	235
5	Biochemistry	1	1	260

Joseph F. Johnston

×

11

Publications

1.8K

Citations

11

H-Index

	Year	Citations
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase Brett P. Monia, Joseph F. Johnston, Thomas Geiger, Nature Medicine Phosphorothioate AntisenseC-raf KinaseAntitumor ActivityMedicineReceptor Tyrosine Kinase	1996	451
Destabilization of Raf-1 by Geldanamycin Leads to Disruption of the Raf-1–MEK–Mitogen-Activated Protein Kinase Signalling Pathway Theodor W. Schulte, Mikhail V. Blagosklonny, L.Y. Romanova, Molecular and Cellular Biology Molecular RegulationMolecular BiologyTumor BiologySignaling PathwayCell Regulation	1996	275
Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. Brett P. Monia, Joseph F. Johnston, David J. Ecker, Journal of Biological Chemistry Oligonucleotide LengthMolecular BiologyAntisense TherapyRna ProcessingBiochemistry	1992	260
Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats Prisca Honoré, Karen Kage, Joseph P. Mikusa, Pain Chronic InflammatoryAcute PainPain MedicineNeuropathic PainMolecular Pain	2002	235
Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha- Brett P. Monia, Joseph F. Johnston, Henri Sasmor, Journal of Biological Chemistry	1996	177
Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C- <i>raf</i> kinase supports an antisense mechanism of action <i>in vivo</i> Brett P. Monia, Henri Sasmor, Joseph F. Johnston, Proceedings of the National Academy of Sciences	1996	138
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Charles M. Rudin, John T Holmlund, Gini F. Fleming, PubMed PathologyRaf-1 ExpressionCancer BiologyTumor BiologyOncology	2001	115
A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma Casey Cunningham, Jon Holmlund, Richard S. Geary, Cancer	2001	101
Selective Inhibition of A-Raf and C-Raf mRNA Expression by Antisense Oligodeoxynucleotides in Rat Vascular Smooth Muscle Cells: Role of A-Raf and C-Raf in Serum-Induced Proliferation Catherine L. Cioffi, M Garay, Joseph F. Johnston, Molecular Pharmacology	1997	47
The Characterization of Atrial Natriuretic Peptide (ANP) Expression by Primary Cultures of Atrial Myocytes Using an ANP-Specific Monoclonal Antibody and an ANP Messenger Ribonucleic Acid Probe* Christopher C. Glembotski, MARION E. ORONZI, Xiaobin Li, Endocrinology	1987	24

Page 1